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Abstract
Background: In colorectal cancer, CDX2 expression is lost in approximately 20% of cases and associated with poor
outcome. Here, we aim to validate the clinical impact of CDX2 and investigate the role of promoter methylation and
histone deacetylation in CDX2 repression and restoration.
Methods: CDX2 immunohistochemistry was performed on multi-punch tissue microarrays (n = 637 patients). Promoter
methylation and protein expression investigated on 11 colorectal cancer cell lines identified two CDX2 low expressors
(SW620, COLO205) for treatment with decitabine (DNA methyltransferase inhibitor), trichostatin A (TSA) (general HDAC
inhibitor), and LMK-235 (specific HDAC4 and HDAC5 inhibitor). RNA and protein levels were assessed. HDAC5 recruitment
to the CDX2 gene promoter region was tested by chromatin immunoprecipitation.
Results: Sixty percent of tumors showed focal CDX2 loss; 5% were negative. Reduced CDX2 was associated with lymph
node metastasis (p = 0.0167), distant metastasis (p = 0.0123), and unfavorable survival (multivariate analysis: p = 0.0008;
HR (95%CI) 0.922 (0.988–0.997)) as well as BRAFV600E, mismatch repair deficiency, and CpG island methylator phenotype.
Decitabine treatment alone induced CDX2 RNA and protein with values from 2- to 25-fold. TSA treatment ± decitabine
also led to successful restoration of RNA and/or protein. Treatment with LMK-235 alone had marked effects on RNA and
protein levels, mainly in COLO205 cells that responded less to decitabine. Lastly, decitabine co-treatment was more
effective than LMK-235 alone at restoring CDX2.
Conclusion: CDX2 loss is an adverse prognostic factor and linked to molecular features of the serrated pathway. RNA/
protein expression is restored in CDX2 low-expressing CRC cell lines by demethylation and HDAC inhibition. Importantly,
our data underline HDAC4 and HDAC5 as new epigenetic CDX2 regulators that warrant further investigation.
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Background
CDX2 is a homeobox protein responsible for the mainten-
ance of the intestinal phenotype [1, 2]. Over the last dec-
ade, CDX2 has been linked to colorectal cancer (CRC)
progression, with reduced expression of the protein asso-
ciated with more advanced tumor stage, vessel invasion,
and metastasis [3–7]. Many studies, including the work by
Dalerba et al., underline the unfavorable survival time in
patients with a complete absence of CDX2 in the tumor
[8], a feature that occurs in approximately 5% of patients
[7, 8]. Furthermore, they demonstrate that CDX2-negative
CRC patients may benefit from chemotherapy, particularly
in a stage II setting [8].
Reduced CDX2 protein expression is related to certain
molecular alterations during colorectal tumorigenesis.
Previous work by our group and others shows that nearly
all sporadic microsatellite unstable (MSI) cancers show
some degree of loss of the protein in the tumor, whether
in a small or substantial percentage of cells [3, 5, 9]. This
loss is not however limited to MSI-high cancers, but is
also found in microsatellite stable (MSS) tumors with
BRAF mutation and high-level CpG island methylator
phenotype (CIMP), in other words, in cancers deriving
from the so-called serrated pathway [10]. More than 20%
of CRCs show some degree (or complete loss) of CDX2
protein in the tumor, which is often reported along with a
preponderance for female gender and right-sided tumor
location, two features frequently associated with serrated
lesions [11].
Since CDX2 mutations are extremely rare events in
CRCs [12], we hypothesized that epigenetic changes, such
as promoter hypermethylation or histone deacetylation
could be responsible for significant downregulation or
absence of CDX2, particularly in the group of tumors
displaying “serrated” molecular features (BRAF mutation,
MSI, and CIMP) [13]. In fact, human serrated adenomas
with high-grade dysplasia have been shown to have signifi-
cantly greater frequencies of CDX2 hypermethylation than
other polyp types (like classical adenomas) [14].
In this study, we aim (1) to validate the clinical relevance
of CDX2 in a large group of CRC patients (n = 637), (2) to
determine whether epigenetic modifications contribute to
CDX2 repression, and (3) to restore CDX2 expression in
vitro by targeting methylation and histone deacetylation.
Methods
Patients
Two retrospective cohorts were investigated. Patient
characteristics are found in Additional file 1: Table S1.
Cohort 1 (Germany)
The cohort initially included 341 primary resected colon
cancer (no rectal cancer) patients treated at the Department
of Surgery at the Technical University Munich (TUM)
hospital, Munich, Germany, between 1993 and 2005. Clin-
ical and pathological features for this cohort included age at
diagnosis, gender, tumor location, TNM stage (UICC 6th
ed.), R classification, and tumor grade. After exclusion of
patients with unavailable tumor material for this study, the
final cohort comprised 252 patients of which 237 (94%) had
information on therapy and survival. Overall 5-year survival
rate was 66.6%.
Cohort 2 (Switzerland)
This cohort encompasses 385 surgically treated CRC pa-
tients. Clinical features retrieved from patient charts were
age at diagnosis, tumor location, and gender. Survival
information, follow-up, and therapy information were
available for 286 (82.9%). Histopathology was re-reviewed
according to the TNM 7th edition and is summarized in
Additional file 1: Table S1. MSI status determined by PCR
was available for 128 patients. Adjuvant treatment for
high-risk stage II and stage III colon cancer consisted of a
5-FU or capecitabine-based chemotherapy (5-FU orcapeci-
tabine ± oxaliplatin). Palliative first-line chemotherapy for
stage IV patients comprised either the FOLFOX, XELOX,
or FOLFIRI regimen with or without bevacizumab/cetuxi-
mab, while anti-EGFR treatment was applied only to
KRAS wild-type patients. Overall 5-year survival was
60.7%.
Ethics, consent, and permissions
The ethics committees of the Klinikum rechts der Isar and
Canton of Bern approved the use of data and patient mater-
ial for this study (nos. 1926/7 and 200/2014, respectively).
Next-generation tissue microarray (ngTMA®) construction
Tissues from all 637 patients were retrieved from the
corresponding archives of the Institutes of Pathology at
the TUM and University of Bern. One to two H&E slides
were sectioned from each block, and the slides were
scanned (P250 Flash II, 3DHistech, Hungary). Digital
slides were annotated using a tissue microarray tool by
placing six to eight different circles onto various
histological areas (Additional file 1: Figure S1) [15]. The
annotated digital slide was then aligned with the tumor
block and cored using a 0.6-mm-diameter TMA tool
(TMA Grandmaster, 3DHistech, Hungary). In addition,
the TMA tool of 1.0 mm diameter was used to punch
out cores from cohort 1, which were placed into tubes
for downstream molecular analysis.
Cell lines and treatment
CRC cell lines (LS174T, T84, LS180, HCT15, HT29,
SW620, COLO205, HCT116, COLO320, LoVo, CaCo2)
were obtained from the American Type Culture Collec-
tion (ATCC, Manassas, VA, USA) and grown in media
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with supplements as described in Additional file 1: Table
S2 under humidified atmosphere of 5% CO2.
Treatment with DNA methyltransferase inhibitor
(DNMTi): 3.5 × 104 COLO205 or SW620 cells were
seeded in six-well plates and treated with 0.5% DMSO,
1.25 μM, 2.5 μM, 5 μM, and 10 μM of decitabine (Stock
50 mM in DMSO, Cat.#S1200, Selleckchem, Houston,
TX, USA) for 48 h.
Treatment with histone deacetylase inhibitors (HDACi):
3.5 × 104 COLO205 or SW620 cells were seeded in six-well
plates and treated with 0.01% DMSO, 50 nM trichostatin A
(Stock 5 mM in DMSO, Cat.# T8552, Sigma-Aldrich, St.
Louis, MO, USA) and 20 nM LMK-235 (Stock 10 mM in
DMSO, Cat.# S7569, Selleckchem) alone or in combination
with 2.5 μM, 5 μM, and 10 μM of decitabine for 48 h.
3.5 × 104 HT29, SW620, LS174T, and LoVo cells were
seeded in six-well plates and treated with 8 × 10−3 DMSO,
5 nM, 10 nM, 20 nM, 40 nM, and 80 nM of LMK-235 for
48 h.
RNA extraction and real-time quantitative RT-PCR (qPCR)
RNA was extracted using the miRCURY RNA Isolation
Kit (Prod.#300110; Exiqon, Vedbaek, Denmark) according
to the manufacturer’s instructions. RNA concentrations
were measured using NanoDrop (Thermo Scientific) and
adjusted to 500 ng/10 μL. cDNA Synthesis Reagent (5xRT
Super Mix, Cat. #B24403; Biotool, Houston, TX, USA)
was added to the diluted RNA, RT-PCR performed using
a Veriti 96-well Thermal Cycler (Model #9902; Applied
Biosystems, Rotkreuz, Switzerland), and H2O added to an
final concentration of 10 ng/μL cDNA. qPCR was per-
formed using 10 ng/μL cDNA and TaqMan Fast Universal
PCR Master Mix (Applied Biosystems). For quantification
of CDX2 and HIC1 mRNA, the Taqman® Gene Expression
Assay Hs01078080_m1 and Hs00359611_s1 (both Applied
Biosystems), respectively, was used. HMBS primers and
probes have been described earlier [16]. Raw Ct values
were normalized to HMBS and to the untreated controls
and are shown as n-fold changes (2 −ΔΔCt analysis).
Western blot analysis
Cell lysates were prepared using a buffer containing 8 mM
urea, 0.5% Triton-X, and proteinase inhibitors (25× PIC
Complete, Rosch), protein concentration determined with
Bradford Assay (Bio-Red Protein Assay; BioRad, Cressier,
Switzerland) and 10 μg samples, mixed with loading buffer
(4× Laemmli Sample Buffer, Cat: #161-0747, BioRad) and
loaded on Mini-Protean TGX Stain Free Gels (12%, 15-well,
Cat. #456-8095; BioRad). After UV activation, proteins were
transferred to a PVDF membrane (0.2 μm PVDF, Cat.
#170-4156; BioRad) using a Trans-Blot Turbo Transfer Pack
(Mini format; BioRad). Membranes were blocked with 5%
TBS-milk for at least 45 min. Blots were incubated with
anti-CDX2 (1:500 in BSA, EPR2764Y—28.8 μg/mL, Rabbit
Monoclonal, Cell Marque; Sigma-Aldrich) over night at
4 °C followed by incubation with anti-rabbit (1:10,000 in
milk; Cell Signalling Technology, Leiden, The Netherlands)
for at least 2 h at RT. Detection took place using ECL (Clar-
ity Western ECL Substrate, Cat. #170-5060; BioRad) and
ChemiDoc (MP, Serial #731BR00765; BioRad). Quantifica-
tion was performed with ImageJ.
Chromatin immunoprecipitation (ChIP)
HEK-293T cells have been transiently transfected using
calcium phosphate [17] and 2 μg of FLAG-HDAC5
(Addgene #32213) expression plasmid in a 10-cm dish.
After 48 h, cells were harvested and processed for ChIP
using the ChIP-IT Express Chromatin Immunoprecipitation
Kit (ChIP-IT Express, Active Motif, Carlsbad, CA, USA) ac-
cording to the manufacturer’s recommendations. In parallel,
FLAG-HDAC5 expression was determined by Western
blotting (data not shown). For immunoprecipitation, 2.5 μg
anti-Flag antibody (Sigma, Cat.#F3165) was used. Anti-
bodies against acetyl-histone H3 (Cell Signalling, Cat.#9715)
and mouse IgG (PP64B, Upstate, Millipore) served as posi-
tive and negative controls, respectively. PCR was performed
using JumpStart Taq (Sigma-Aldrich) and the following
primers, specifically selected to cover a 2500-bp genomic
region upstream of the transcription start site (TSS) of the
CDX2 gene: 2000–2500 bp, F: 5′-CTTTCCATGGCTGG
AGCACT-3′, R: 5′-CGCTGGCTAATTGTCCCTGT-3′;
1500–2000 bp, F: 5′-CATTCCCACCCCATCAGGTC-3′,
R: 5′-CCAAGGAGCTGTGCACTCAA-3′; 1000–1500 bp,
F: 5′-ACAGACAAGTGCAGGTCTCC-3′, R: 5′-CCCA
GCTCGGTTTCAGCA-3′; and TSS–500 bp, F: 5′-TGGA
GGTTAAAGTGCACCAGGT-3′, R: 5′-GACACCAAT
GGTTGGAGACG-3′. As a positive control for HDAC5
recruitment, we amplified a genomic region of the HDAC5
repressed fibroblast growth factor 2 (FGF2) gene using the
following published primers: F: 5′-TGGAGGTTAAAGTG
CACCAGGT-3′ and R: 5′-GACACCAATGGTTGGAGAC
G-3′ [18].
DNA extraction and CDX2 methylation analysis
Genomic DNA was extracted from selected tumoral area of
FFPE tissues using QIAamp DNA FFPE Tissue Kit (Qiagen;
Hilden, Germany). Bisulfite conversion and pyrosequencing
were used to analyze CDX2 methylation in two different
promoter regions. Both regions are located on chromosome
13, GRCh38.p7 Primary Assembly (NC_000013), region 1:
27970684-27970645 and region 2: 27970508-27970478.
PCR conditions and details on primer sequences and region
to analyze are outlined in Additional file 1: Methods.
MS-MLPA for CIMP status
Methylation-specific multiplex ligation-dependent probe
amplification (MS-MLPA) was performed according to
standard protocol for CIMP status evaluation and BRAFV600E
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mutation. Promoter methylation of CACNA1G, IGF2, NEU-
ROG1, RUNX3, SOCS1, CDKN2A,MLH1, and CRABP1 was
analyzed by SALSA MLPA probemix ME042-C1 (MRC
Holland, Amsterdam, Netherlands). A gene was considered
methylated when one fourth (25%) or more probes were at
least 30% methylated. This cutoff was set as it corresponds
with the highest background methylation value in the healthy
tissue control.
Immunohistochemistry and in situ hybridization
All ngTMA blocks were sectioned at 2.5 μm, and immuno-
histochemistry was performed on an automated immunos-
tainer (Leica Bond Rx or Ventana Benchmark Ultra) for
CDX2 (clone ERP2764Y, Cell Marque, 1:400, Tris 95° 30′),
BRAFV600E protein (clone VE1, Roche, CC1 99° 72′), and
MLH1 (clone ES05, Leica Novocastra, 1:200, Tris 95° 30′).
CDX2 and MLH1 protein expression was evaluated by
estimating the number of immunoreactive nuclei in each
tumor punch, then an average positive count across all
cores from the same patient lead to the final marker value
for statistical analysis. Since CDX2 is normally present in
all cells of the normal colonic mucosa, we quantified the
percentage of immunoreactive cells in the tumor then de-
fined a “reduced or loss of” expression when less than 100%
of cells were stained and a complete loss of expression
when 0% of cells where stained. VE1 was scored as positive
or negative. Any doubt regarding positive staining of VE1
was confirmed by pyrosequencing. RNA expression was
evaluated semi-quantitatively [19] across all tumor punches
in cohort 1 using RNAscope 2.0 FFPE assay and probes for
CDX2, the bacterial gene dapB, as negative control and the
housekeeping gene PPIB as positive control (Advanced Cell
Diagnostics, Inc.). Scoring was performed as previously
described [17]. Briefly, score 0 = no staining, score 1 = diffi-
cult to see under 40x, score 2 = difficult to see under 20x
but easy under 40x, score 3 = difficult to see under 10x but
easy under 20x, and score 4 = easy to see under 10x.
Immunohistochemistry was also performed on cell lines.
1 × 106 cells of COLO205 and SW620 cell lines were
seeded, treated with decitabine and/or TSA or LMK-235
and harvested using trypsin after 48 h and 72 h. Cells were
washed with PBS, formalin-fixed and paraffin embedded
(FFPE), and immunohistochemically stained for CDX2.
Slides were scanned with a Pannoramic 250 Flash II
(3DHistech Ltd., Budapest, Hungary). Cell quantification
was performed with the open source image analysis
software QuPath [20], using watershed cell detection on
optical density sum images and subsequent random trees
classification of the detected cells.
Statistics
Descriptive statistics, non-parametric Wilcoxon rank
sum test or chi-square tests were used to analyze differ-
ences in CDX2 staining with categorical features.
Survival time analysis was performed using both
log-rank tests and Kaplan-Meier curves and Cox propor-
tional hazards regression models in multivariable analysis,
adjusting for potential confounding factors. Hazard ratios
and 95%CI were used to determine the effect differences.
Spearman correlation coefficients were calculated to de-
termine the strength of relationship between methylation
and protein expression. Student’s t test was used to
compare mean methylation percentage in CDX2-positive
or CDX2-negative cell lines. For statistical analysis of four
biological replicates of qPCR and Western blot results,
Mann-Whitney test was performed. p values < 0.05 were
considered statistically significant. No adjustment for
multiple comparisons was performed [21]. Analyses were
performed using SAS V9.3 (The SAS Institute, Cary, NC)
and PRISM, GraphPad Software.
Results
Distribution of CDX2 protein expression scores
CDX2 protein expression ranged from 0 to 100%.
Additional file 1: Figure S2 highlights the distribution of
expression from cohort 2 (A) as well as representative
immunostaining (B-D). Thirty-nine patients (5.0%)
showed a complete absence of CDX2 protein in the
tumor. The percentage of CDX2 immunostained tumor
cells was 66% on average, with a median of 78.8%. In
terms of different tumor areas, there was no difference
in expression between the tumor center and invasion
front; however, tumor budding cells were frequently seen
with an absent CDX2 staining.
Relationship between mRNA ISH scores and protein
expression
One thousand four hundred sixty-one punches were
evaluated for mRNA ISH with corresponding protein data.
There was a strong and statistically significant correlation
between the CDX2 protein expression scores in the tumors
and the corresponding mRNA ISH scores (r = 0.99, p <
0.0001) indicating that RNA expression and protein expres-
sion were highly associated. The mean percentage of CDX2
protein expression across all tumors was 44.2% (score 0),
52.7% (score 1), 65.8% (score 2), 76.2% (score 3), and 90.8%
(score 4) (p < 0.0001) (Additional file 1: Figure S3).
Clinicopathological features associated with progressive
CDX2 loss
In cohort 1, there was a significant correlation between
reduced CDX2 expression and female gender (p = 0.0338);
more advanced pT classification (p = 0.0068), lymph node
metastasis (p = 0.0167), and distant metastasis (p =
0.0123); and higher tumor grade (p = 0.0163) (Table 1).
Similar correlations could be found for cohort 2 with
significant associations between reduced CDX2 and histo-
logical subtype (p = 0.009), right-sided tumor location (p
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= 0.0135), more advance pT stage (p = 0.0002), distant
metastasis (p = 0.0337), higher tumor grade (p = 0.0004),
lymphatic vessel invasion (p = 0.00136), and a trend to
venous vessel invasion (p = 0.0706).
CDX2 is an adverse and independent prognostic factor
Survival analysis was performed on the combined set of
patients; 599 patients were available for analysis. In
univariate analysis, reduced CDX2 expression was signifi-
cantly related to worse overall survival (Cox regression
analysis using percentage of positive cells) (p = 0.0008; HR
(95%CI) 0.992 (0.988–0.997)). The survival effect of CDX2
was also evaluated using two different cutoff values, found
in the literature: 0% (versus any expression) [8] and a
threshold of 75% (focal versus diffuse) [10]. Thirty-four of
599 patients had tumors with 0% expression, and 16
(47.1%) died over the course of follow-up (Fig. 1).
Five hundred and sixty-five patients had tumors with any
CDX2 expression, and 139 died during follow-up. In both
instances, there was a significant and marked effect of
CDX2 absence/loss on survival. However, of the two cutoffs
interrogated, only the 0% cutoff was found to have an
independent prognostic effect on outcome, after adjusting
for TNM stage and postoperative therapy (Table 2). Our
analysis of CDX2-negative patients with and without
chemotherapy shows no difference in the overall survival
with postoperative treatment. However, due to low statis-
tical power of the negative subgroup, we cannot adequately
evaluate the survival benefit with chemotherapy here.
CDX2 loss is associated with molecular features of the
serrated pathway
BRAFV600E mutation was found in 10.4% of patients, while
mismatch repair (MMR) deficiency in 12.2% of all patients
in both cohorts. Expression of CDX2 was significantly
reduced in tumors with BRAFV600E mutations (p = 0.0044
cohort 1; p < 0.001 cohort 2) and tumors with defective
MMR (p = 0.0077 cohort 1; p = 0.0005 cohort 2).
Additional file 1: Figure S4 outlines the progressive loss of
CDX2 protein with changes in both MMR status (proficient
or deficient) and BRAF status (wild-type or mutation)
across both cohorts (n = 590). In comparison to
MMR-proficient/BRAF WT tumors (70.1% CDX2), those
with MMR-deficient/BRAFV600E-mutated cancers (29.3%
CDX2) have a significantly reduced expression (p < 0.0001).
CDX2 promoter methylation is a mechanism of protein
loss in CRC cell lines
To test whether hypermethylation of CDX2 promoter
could explain mRNA and protein loss in CRCs, 11 dif-
ferent CRC cell lines were fixed in formalin, embedded
in paraffin, and immunostained for CDX2. Diffuse,
partial, or absent CDX2 expression was evaluated and
correlated to the analysis of methylation status at two
Table 1 Association of progressive CDX2 loss with
clinicopathological features in two cohorts
Clinicopathological
feature
COHORT 1 (n = 252) COHORT 2 (n = 385)
CDX2%
(mean/median)
p value CDX2%
(mean/median)
p value
Gender
Male 61.5/71.7 0.0338 72.6/85 0.5675
Female 52.6/56.7 67.6/83.1
Histological subtype
Adeno n/a 71.9/85 0.009
Mucinous n/a 66.6/75
Other n/a 41.9/51.3
Tumor location
Left 58.2/60.8 0.812 69.5/86.3 0.0135
Right 57.3/65.8 75.6/90
Rectum – 68.1/75
pT
pT1 62.3/75.0 0.0068 83.8/93.8 0.002
pT2 55.8/63.3 68.7/82.5
pT3 55.9/64.5 73.7/84.4
pT4 37.0/26.7 56.3/66.7
pN
pN0 61.6/71.7 0.0167 72.5/86.3 0.1891
pN1-2 52.6/58.8 69.0/82.5
pM
pM0 (c) 65.2/76.7 0.0123 72.5/85 0.0337
pM1-2 48.9/60 60.2/71.3
Tumor grade
G1-2 65.4/76.7 0.0163 74.8/85 0.0004
G3 47.0/40.0 57.2/70.4
Lymphatic invasion
L0 n/a – 74.7/88.8 0.0136
L1 n/a 68.9/75.8
Venous invasion
V0 n/a – 74.2/84.4 0.0706
V1 n/a 67.7/80
Perineural invasion
Pn0 n/a – 70.0/80 0.7978
Pn1 n/a 69.8/85
BRAF
Wild-type 59.6/66.7 0.0044 76.0/87.5 < 0.0001
Mutated 43.0/38.3 26.4/4.4
MMR status
Deficient 48.1/47.5 0.0077 43.5/50 0.0005
Proficient 61.8/71.7 69.5/79.4
n/a not available
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promoter regions. LS174T, T84, LS180, and HCT-15
were moderately to strongly positive and showed minimal
methylation percentages at both sites. In contrast, HT29,
SW620, COLO205, and HCT-116 showed a complete
absence of CDX2 or only few CDX2-positive cells at the
protein level and a high (> 80%) degree of methylation
(Fig. 2). The association between higher percentage of
methylation and absence of protein expression was signifi-
cantly correlated (p = 0.0295). The remaining three cell
lines, LoVo, CaCo2, and COLO320, showed no correl-
ation between protein expression and methylation status.
CDX2 promoter hypermethylation and protein expression
in CRCs
We selected 39 patients from cohort 1, including all tumors
with BRAF mutation and MMR deficiency (n = 9), and per-
formed both a CDX2 promoter methylation analysis as well
as CIMP analysis. All nine cases were CIMP-high. CDX2
hypermethylation (> 20% methylation across all CpG sites)
was found in 23 patients. Pyrosequencing results for these
patients can be found in Additional file 1: Table S3. There
was a striking inverse correlation between CDX2 protein
and percentage of methylation, which was limited to the
serrated tumor group (r = − 0.7). Cancers without these ser-
rated molecular features had no correlation between CDX2
protein expression and methylation (r= − 0.07).
DNA methyltransferase inhibitor (DNMTi) treatment
restores CDX2 expression
To test whether global demethylation can restore CDX2
expression, we treated two CRC cell lines (COLO205 and
SW620) showing low/absent CDX2 expression with the
DNMTi, decitabine. Upon 48 h treatment with decitabine,
a significant 2- and 15-fold induction of CDX2 RNA could
be observed for SW620 and COLO205, respectively, with
the latter showing a dose-dependency (Fig. 3a). Import-
antly, SW620 cells show a 4-fold higher CDX2 basal level
expression of mRNA compared to COLO205 cells.
As a control for the efficiency of the decitabine treatment,
we determined the mRNA induction of hypermethylated in
cancer 1 (HIC1) in SW620 and COLO205 cells, a gene with
known promoter hypermethylation in cancer. We found a
significant increase in HIC1 mRNA levels in both cell lines
upon decitabine treatment (Additional file 1: Figure S5).
On a protein level, a major induction in CDX2 protein
was observed in SW620 and to a lesser extent in COLO205
cells, as seen on both Western blot and immunohistochem-
istry (Figs. 3b).
Combination of DNMTi and HDACi or HDAC4/5i
treatment improves restoration of CDX2 expression
Since DNA demethylation affects CDX2 restoration, we
asked whether other epigenetic modifications, in particular,
histone acetylation could have an additional impact on
CDX2 gene regulation. In a first step, we treated COLO205
and SW620 cells with a general HDACi, trichostatin A
(TSA). We observed an up to 10-fold induction of CDX2
RNA upon TSA treatment alone and an up to 23-fold
induction of CDX2 RNA when combined with decitabine
in COLO205 cells (Fig. 4a), as well as on protein level
(Fig. 4b, c). This result indicates that the combination treat-
ment of TSA and decitabine is more effective at restoring
CDX2 expression than decitabine or TSA alone in
COLO205. In comparison, TSA treatment alone or in
combination did not have a comparable impact on CDX2
restoration in SW620 cells (Additional file 1: Figure S6).
Since TSA is a general HDACi with varying specificity in
HDAC inhibition, we asked whether inhibition of specific
HDACs might be involved in CDX2 regulation.
We therefore treated cells with LMK-235, a specific
inhibitor of HDAC4 and HDAC5. In COLO205, our
results show an even more pronounced induction of
CDX2, both upon single-treatment with LMK-235 (up to
25-fold) or in combination with decitabine (up to
35-fold) (Fig. 4a). These results are again underlined by
Fig. 1 Kaplan-Meier survival curves showing survival time differences using two different cutoff values for CDX2. a Complete absence of staining
(0%). b Loss of CDX2 with less than 75% staining. Log-rank test
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increased protein expression assessed by Western blot-
ting and immunohistochemistry (Fig. 4b, c). A similar ef-
fect can be observed in SW620 cells, namely a marked
increase in both CDX2 RNA and protein is seen upon
LMK-235 treatment alone and in combination with
DNMTi (Additional file 1: Figure S6).
Next, we asked whether CDX2 protein restoration could
be induced by LMK-235 in HT29, a cell line known to be
only minimally responsive to DNMTi treatment. Indeed,
upon LMK-235 treatment, HT29 cells showed a signifi-
cant and dose-dependent increase of CDX2 on RNA level
and remarkably on protein level as well (Fig. 5). We
further observed a pronounced CDX2 induction upon
LMK-235 treatment, independent of CDX2 promoter
methylation status of two other cell lines, LS174T and
LoVo (Additional file 1: Figure S7).
To test if HDAC5 localizes to the CDX2 promoter region
and is directly involved in repression CDX2 gene expression,
Table 2 Multivariable analysis of CDX2 (absence versus any
positive expression) adjusting for TNM stage and postoperative
therapy
HR (95%CI) p value
CDX2
Negative 1.0
Positive 0.35 (0.17–0.71) 0.0037
TNM stage
TNM I (vs IV) 8.85 (4.05–19.2) < 0.0001
TNM II (vs IV) 6.33 (3.65–10.9) < 0.0001
TNM III (vs IV) 3.62 (2.18–6.02) < 0.0001
Postoperative therapy
None 1.0
Treated 1.01 (0.83–1.23) 0.9172
Fig. 2 Eight colorectal cancer cell lines showing the expected inverse correlation between hypermethylation percentage at two CDX2 promoter
sequences and CDX2 protein expression
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we performed an HDAC5 chromatin immunoprecipitation
(ChIP) assay. Indeed, HDAC5 is found at a genomic region
upstream of the transcriptional start site indicating direct
CDX2 repression by HDAC5 (Fig. 6). As a positive control for
HDAC5 repressed gene expression, we amplified a genomic
region of the fibroblast growth factor 2 (FGF2) gene [18].
In summary, combining decitabine with the HDAC4/5
inhibitor LMK-235 allows for improved CDX2 expression
in CRC cells, particularly in cells with a low sensitivity to
DNMT inhibition, whereby HDAC5 is directly involved in
CDX2 gene expression by localizing to the CDX2 gene
promoter region.
Discussion
The novel findings of this study show that CDX2 in
CRC can be regulated by either promoter methylation
and more markedly by histone acetylation. In particular,
treatment of cell lines by specific HDAC4 and HDAC5
inhibitor LMK-235 (with and without DNMTi) leads to
a marked upregulation and re-expression of CDX2 RNA
and protein, implying that both enzymes are involved in
the repression of CDX2 transcription.
CDX2 is an important prognostic factor. Its loss has been
linked to more aggressive tumor features such as TNM
stage, metastasis, and vessel invasion [3–5, 8, 10, 19]. Recent
reports have shown that a complete loss of protein (0%
staining) provides information on overall survival and
chemotherapy benefit [8]. However, our study demonstrates
that any loss of CDX2 can be informative, with a reduction
in protein related to poorer clinical outcome in a
stage-independent manner. Nolte and colleagues published
a detailed analysis of CDX2 by digital image analysis on a
a
b
Fig. 3 Decitabine significantly restores CDX2 expression in CDX2-negative CRC cell lines. a Upper panel: qPCR analysis of CDX2-negative COLO205 and
SW620 cells treated with increasing concentrations of the DNMTi decitabine (1.25 μM, 2.5 μM, 5 μM) for 48 h. Data were normalized to the HMBS
housekeeping gene and are shown as n-fold regulation compared with DMSO-treated cells. MWU: ***p < 0.001, (n = 4) Lower panel: CDX2 Western
blot analysis of cells treated as above. Total protein is shown as a loading control. b Immunohistochemistry (IHC) analysis of COLO205 and SW620
cells treated with 5 μM decitabine for 48 h. Quantification of CDX2 expression was done using the image analysis software QuPath
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similar number of cases, highlighting the range of possible
CDX2 values expressed by CRCs [22]. They used the full
information from staining intensity and percentage of posi-
tive cells and underline that any loss of protein is related to
more aggressive features. Our results are in line with this
observation: here, we validate the independent prognostic ef-
fect of both progressive and complete CDX2 loss of protein
expression. Regardless of the large number of patients in this
study (n = 599 for survival analysis), we cannot confirm the
predictive effect of CDX2 to chemotherapy response.
a c
b
Fig. 4 Improved CDX2 restoration in COLO205 cells upon combining DNMTi and HDACi treatment. a qPCR analysis of COLO205 cells treated for
48 h with DNMTi decitabine (2.5 μM, 5 μM, 10 μM) alone and in combination with the general HDACi trichostatin A (TSA; 50 nM) or the specific
HDAC4/5 inhibitor LMK-235 (20 nM). Analysis as in Fig. 5a. MWU: ***p < 0.001, (n = 4). b CDX2 Western blot analysis of COLO205 cells treated as
in a. Total protein is shown as a loading control. c Immunohistochemistry (IHC) analysis of COLO205 cells treated with decitabine (5 μM), TSA
(50 nM), or LMK-235 (20 nM) alone or combination treatments with decitabine and TSA or LMK-235
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Our group has previously shown that a loss of CDX2 is
specific for BRAFmutation and for the CIMP-high pheno-
type and that both MSI and MSS cancers may show loss
of CDX2 in this context [9, 10]. Here, we validate these
findings by showing a gradual reduction in the percentage
of positive cells with single (MSI or BRAFV600E) and
double (MSI + BRAFV600E) alterations, findings that are in
line with work from other groups [3, 23, 24]. Since the
molecular characteristics of CDX2-negative tumors are
predominantly those with BRAF mutation, CIMP, and
MSI and frequently found in female patients with
right-sided tumors, we hypothesized that CDX2 loss could
play a functional role in tumors derived from the serrated
pathway, a route of CRC development originating from
the serrated adenoma. Dhir and colleagues report that
CDX2 is lost in high-grade dysplastic areas of sessile ser-
rated adenomas and may occur due to promoter hyper-
methylation, an observation that is directly in line with
our hypothesis in cancers [14]. We therefore investigated
hypermethylation as a possible mechanistic reason for the
gradual loss of the CDX2 protein.
Of 11 CRC cell lines investigated, we initially selected
two low-expressing cell lines (SW620 and COLO205) to
evaluate whether mRNA and protein could be re-expressed
upon demethylation with a broad DNMTi, decitabine,
already used in clinics for treatment of some patients with
myelodysplastic syndrome (MDS) and acute myeloid
leukemia (AML). Here, we could demonstrate a strong
re-expression of CDX2 at mRNA and protein level, thus
providing a functional link between promoter methylation
and protein. Although restoration of CDX2 has been previ-
ously shown for COLO205 [12], reports show that HT29
cells are not induced to express CDX2 at the protein level
upon DNMTi treatment [25, 26]. The contribution of DNA
promoter hypermethylation to CDX2 gene silencing seems
to vary among different CRC cells possibly reflecting a simi-
lar situation in CRC patients.
We next investigated whether HDAC inhibition could
help to further restore CDX2 RNA and protein either
alone or in combination with decitabine in CRC cells. We
hypothesized that the more open state of chromatin
coupled to demethylation would have a synergistic or
additive effect on restoration of CDX2. We found that
combining decitabine with a general HDACi TSA resulted
in marked CDX2 induction. However, LMK-235, a specific
HDAC4/5 inhibitor, had a considerably more potent effect
on CDX2 restoration as compared to TSA, independent
of response to decitabine treatment. Highlighting this
further, protein expression of CDX2 could be restored in
HT29 cells upon LMK-235 treatment, a result that is not
seen upon treatment with DNMTi. Furthermore, we
found direct recruitment of HDAC5 to the CDX2 pro-
moter region indicating that this HDAC directly represses
CDX2 gene transcription. Further, studies are needed to
investigate if HDAC4 and other HDACs are also involved
in repressing CDX2 gene expression.
Fig. 5 Upper panel: qPCR analysis of CDX2-negative HT29 cells treated with increasing concentrations of the DNMTi decitabine (1.25 μM, 2.5 μM,
5 μM, 10 μM) for 48 h and increasing concentrations of the HDAC4/5i LMK-235 (5 nM, 10 nM, 20 nM, 40 nM, 80 nM). Data were normalized to
the HMBS housekeeping gene and are shown as n-fold regulation compared with DMSO-treated cells. MWU: ***p < 0.001, (n = 4). Lower panel:
CDX2 Western blot analysis of the three highest concentrations for both compounds of HT29 cells treated as above. Total protein is shown as a
loading control. Percentage indicates amount of protein normalized to respective DMSO controls
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In human disease, it appears that loss of CDX2 is an
early event in the progression of cancers via the serrated
pathway [14] [27]. In our study, we can show that methy-
lation of CDX2 in cancers with the serrated profile have
different degrees of hypermethylation that correlate with
CDX2 protein in a dose-dependent manner. Few studies
have examined methylation of CDX2. Wang and
colleagues determine that the rate of hypermethylation of
CDX2 is 78.5% in colorectal cancers when compared to a
normal population control (43.5%). However, this normal
control group was composed of patient with colorectal
polyps, likely explaining the high number of hypermethy-
lated cases [27]. CDX2 has on the one hand been de-
scribed as a tumor suppressor and its loss is associated
with development of adenomas in mice [28]. On the other,
it is reported as an amplified lineage-survival oncogene,
sometimes amplified in CRCs and required for prolifera-
tion and survival of CRC cells [29]. Although amplification
of CDX2 was not investigated in this study, future studies
may focus on this mechanism as an alternative explan-
ation for the lack of correlation between DNA methyla-
tion and protein expression outside of the serrated
tumors. Since CDX2mRNA (detected by ISH) and protein
were so tightly linked in this study, we speculate that
post-transcriptional or post-translational modification of
CDX2 may play only a minor role in CRC progression.
Conclusion
Our findings underline the independent and adverse prog-
nostic effect of CDX2 and the involvement of epigenetic
modifications in the silencing of CDX2 gene expression, in
particular of promoter methylation and histone deacetyla-
tion by HDAC4 and HDAC5. These results open a new
epigenetic landscape into CDX2, which should be further
investigated.
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